In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 201 to 210 of 373

TitleTypeExpected publication date
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]Technology appraisal guidanceTBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]Technology appraisal guidance
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]Technology appraisal guidanceTBC
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]Technology appraisal guidance
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096]Technology appraisal guidanceTBC
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221Technology appraisal guidance
Nemolizumab for treating prurigo nodularis [ID6451]Technology appraisal guidanceTBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]Technology appraisal guidance
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All